Seladelpar has a good reputation and is effective.

Seladelpar(Seladelpar) is a new type of selective peroxisome proliferator-activated receptor delta (PPAR-δ) agonist. It is mainly used to treatPrimary Biliary Cholangitis (Primary Biliary Cholangitis (PBC)), especially for patients who have poor response to the existing first-line drug ursodeoxycholic acid (UDCA). PBC is a chronic autoimmune liver disease. Patients often present with symptoms such as cholestasis, abnormal liver function, and chronic pruritus. Seladelpar can improve liver damage indicators and relieve related symptoms by regulating bile acid metabolism and inflammatory pathways.

In overseas clinical studies, Seladelpar has shown significant efficacy. In a major study involving 193 adults with PBC, patients received Lyvdelzi or placebo in addition to continuing to take UDCA. Study results showed that approximately 62% of patients treated with Lyvdelzi achieved significant improvements in alkaline phosphatase (ALP) and total bilirubin levels in the blood, while only approximately 20% of patients in the placebo group achieved the same effect. This shows that Seladelpar has obvious advantages in improving liver function indicators, and its mechanism of action directly targets cholestasis and inflammatory response, providing a new treatment idea for the management of chronic PBC.

In addition to the improvement of biochemical indicators, Seladelpar also shows good results in relieving itching caused by cholestasis. PBC patients often suffer from itching that affects their sleep and quality of life, and Seladelpar can improve this symptom and improve the comfort of daily life. Feedback from overseas patients generally believes that the drug is well tolerated, convenient to take orally, and the dosage is simple and can be completed once a day, reducing the burden of complex medication. Most patients can feel an improvement in their quality of life within a few weeks of taking the drug, and laboratory indicators show a gradual recovery of liver function.

Overall,Lyvdelzi has received good reviews overseas and in clinical practice, providing a practical treatment option for patients with chronic cholestatic diseases.

Reference materials:https://go.drugbank.com/drugs/DB12390